
Pacira BioSciences downgraded after Viatris announces $1.65B acquisition deal.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...





